B. animalis subsp. lactis LMG P-21384 and changes in bowel function (further assessment)

Tabs

Article
Bifidobacterium animalis subsp. lactis LMG P-21384, bowel function, health claims
First published in the EFSA Journal
7 August 2012
Adopted
28 June 2012
Type
Scientific Opinion
Abstract

Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to provide a scientific opinion on a health claim pursuant to Article 13 of Regulation (EC) No 1924/2006 in the framework of further assessment in relation to Bifidobacterium animalis subsp. lactis LMG P-21384 and changes in bowel function. The food constituent that is the subject of the health claim, B. animalis subsp. lactis LMG P-21384, is sufficiently characterised. The claimed effect, changes in bowel function such as reduced transit time, more frequent bowel movements, increased faecal bulk, or softer stools may be a beneficial physiological effect, provided that it does not result in diarrhoea. No human intervention studies were provided from which conclusions could be drawn for the scientific substantiation of the claim. On the basis of the data presented, the Panel concludes that a cause and effect relationship has not been established between the consumption of B. animalis subsp. lactis LMG P-21384 and changes in bowel function.

Panel members at the time of adoption
Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser-Berthold, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, Hendrik van Loveren and Hans Verhagen
Panel on Dietetic Products, Nutrition and Allergies
Contact
nda [at] efsa.europa.eu
doi
10.2903/j.efsa.2012.2851
EFSA Journal 2012;10(8):2851 [14 pp.].
Question Number
On request from
European Commission
Print on demand
Number of Pages
14